Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial
European Journal of Cancer · 2025-06 · 222 · 115438
DOI: 10.1016/j.ejca.2025.115438 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2025-06. Verfasst von Giacomo Biganzoli und 20 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) "L. Sacco" & DSRC, LITA Vialba campus, …. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Body Mass Index, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Research Council, Cancer Foundation, Fondation contre le Cancer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) "L. Sacco" & DSRC, LITA Vialba campus, University of Milan, Milan, Italy.
- KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, Leuven, Belgium.
- KU Leuven, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, Leuven, Belgium; University Hospitals Leuven, Department of Pathology, Leuven, Belgium.
- Gynecologic Oncology and Multidisciplinary Breast Center, University Hospitals UZ-Leuven, KU Leuven, Leuven, Belgium.
- Medical Oncology Department, CHU Liège, Liège University, Liège, Belgium.
- Division of Medical Senology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Förderung
- European Research Council
- Cancer Foundation
- Fondation contre le Cancer
- Novartis
- Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung
- ETOP IBCSG Partners Foundation
Zitieren
APA
Biganzoli, G., Isnaldi, E., Richard, F., Marano, G., Boracchi, P., Maetens, M., Floris, G., Neven, P., Jerusalem, G., Munzone, E., Hitre, E., Gombos, A., Thompson, A., Aebi, S., Kammler, R., Dell'Orto, P., Viale, G., Regan, M. M., Colleoni, M., …, & Desmedt, C. (2025). Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial. European Journal of Cancer, 222, 115438. https://doi.org/10.1016/j.ejca.2025.115438
Vancouver
Biganzoli G, Isnaldi E, Richard F, Marano G, Boracchi P, Maetens M, et al. Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial. European Journal of Cancer. 2025;222:115438. doi:10.1016/j.ejca.2025.115438
BibTeX
@article{Biganzoli2025,
author = {Biganzoli, Giacomo and Isnaldi, Edoardo and Richard, François and Marano, Giuseppe and Boracchi, Patrizia and Maetens, Marion and Floris, Giuseppe and Neven, Patrick and Jerusalem, Guy and Munzone, Elisabetta and Hitre, Erika and Gombos, Andrea and Thompson, Alastair and Aebi, Stefan and Kammler, Roswitha and Dell'Orto, Patrizia and Viale, Giuseppe and Regan, Meredith M and Colleoni, Marco and Biganzoli, Elia and Desmedt, Christine},
title = {Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial},
journal = {European Journal of Cancer},
year = {2025},
volume = {222},
pages = {115438},
doi = {10.1016/j.ejca.2025.115438}
}
EUVIMED